IN2012DN02345A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02345A
IN2012DN02345A IN2345DEN2012A IN2012DN02345A IN 2012DN02345 A IN2012DN02345 A IN 2012DN02345A IN 2345DEN2012 A IN2345DEN2012 A IN 2345DEN2012A IN 2012DN02345 A IN2012DN02345 A IN 2012DN02345A
Authority
IN
India
Prior art keywords
nucleic acid
stranded
methods
tlrs
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Bruce A Sullenger
Jaewoo Lee
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of IN2012DN02345A publication Critical patent/IN2012DN02345A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2345DEN2012 2009-09-16 2010-09-16 IN2012DN02345A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24309009P 2009-09-16 2009-09-16
PCT/US2010/002516 WO2011034583A2 (en) 2009-09-16 2010-09-16 Inhibition of endosomal toll-like receptor activation

Publications (1)

Publication Number Publication Date
IN2012DN02345A true IN2012DN02345A (enExample) 2015-08-21

Family

ID=43759220

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2345DEN2012 IN2012DN02345A (enExample) 2009-09-16 2010-09-16

Country Status (6)

Country Link
US (3) US9468650B2 (enExample)
EP (1) EP2477641B1 (enExample)
CN (1) CN102639142A (enExample)
CA (1) CA2774460C (enExample)
IN (1) IN2012DN02345A (enExample)
WO (1) WO2011034583A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682580A1 (en) 2007-03-30 2008-10-09 Duke University A method of modulating the activity of a nucleic acid molecule
IN2012DN02345A (enExample) 2009-09-16 2015-08-21 Univ Duke
WO2012151575A2 (en) 2011-05-05 2012-11-08 Duke University A method of controlling coagulation
WO2014169043A1 (en) * 2013-04-09 2014-10-16 Duke University Anti-inflammatory agents and methods of using the same
US10066323B2 (en) 2014-04-16 2018-09-04 Duke University Electrospun cationic nanofibers and methods of making and using the same
US12514872B2 (en) 2015-11-04 2026-01-06 Duke University Polycationic polymers for use in treating and detecting cancer
CN109982707A (zh) 2016-09-16 2019-07-05 杜克大学 血管性血友病因子（vwf）靶向剂及其使用方法
WO2018119422A1 (en) 2016-12-22 2018-06-28 Duke University Polycationic microfibers and methods of using the same
JP7231229B2 (ja) 2017-03-23 2023-03-01 デューク ユニバーシティ 細胞外アプタマー染色のアンチドート媒介性解除
EP3630194A4 (en) * 2017-05-30 2021-03-17 The Trustees of Columbia University in the City of New York CATIONIC NUCLEIC ACID TRAP AND ITS USES
US11713464B2 (en) 2017-09-08 2023-08-01 Duke University Nucleolin-targeting aptamers and methods of using the same
WO2021016924A1 (zh) * 2019-07-31 2021-02-04 中山大学 可用于治疗银屑病的阳离子聚合物及颗粒
EP4249913A1 (en) * 2022-03-22 2023-09-27 Centre Hospitalier Universitaire de Nîmes Toll-like-receptor 3 inhibitor for preventing and/or treating disorders in patients with a personal history of venous thromboembolism (vte)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919761A (en) 1992-08-14 1999-07-06 The Board Of Regents Of The University Of Michigan Peptides for heparin and low molecular weight heparin anticoagulation reversal
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
CA2421391A1 (en) 2000-09-08 2002-03-14 Mekbib Astatke Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
WO2002053185A2 (en) 2001-01-05 2002-07-11 Intercell Ag Anti-inflammatory use of polycationic compounds
RU2003129062A (ru) 2001-03-08 2005-04-10 Мерк Патент ГмбХ (DE) Модифицированный протамин с уменьшенной иммуногенностью
SG2011071982A (en) 2001-05-25 2016-09-29 Univ Duke Modulators of pharmacological agents
AUPR604101A0 (en) 2001-06-29 2001-07-26 Unisearch Limited Aptamers
US20050136040A1 (en) * 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
US20030157030A1 (en) 2001-11-02 2003-08-21 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
US20030180250A1 (en) 2002-03-22 2003-09-25 Council Of Scientific And Industrial Research Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
BR0315198A (pt) 2002-10-09 2005-08-30 Insert Therapeutics Inc Materiais e composições à base de ciclodextrina e usos relacionados aos mesmos
JP2006528492A (ja) 2003-07-15 2006-12-21 カリフォルニア インスティテュート オブ テクノロジー 改良されたインヒビター核酸
US20050256071A1 (en) 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
JP4718541B2 (ja) 2004-04-22 2011-07-06 リガド・バイオサイエンシーズ・インコーポレーテツド 改良された凝固因子調節剤
US8080245B2 (en) 2004-08-04 2011-12-20 University Of Massachusetts Anti-pathogen immunoadhesins
GB0422877D0 (en) 2004-10-14 2004-11-17 Univ Glasgow Bioactive polymers
EP1866414B9 (en) 2005-03-31 2012-10-03 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
US7611835B2 (en) 2005-09-30 2009-11-03 Battelle Memorial Institute Process for preparing multilayer enzyme coating on a fiber
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
US20090048193A1 (en) 2006-05-26 2009-02-19 Rusconi Christopher P Administration of the REG1 anticoagulation system
EP3669894A3 (en) * 2006-06-30 2020-08-26 Syntab Therapeutics GmbH Novel multifunctional compounds for pharmaceutical purposes
US20110118187A1 (en) 2006-10-19 2011-05-19 Duke University Reversible platelet inhibition
US20100028402A1 (en) 2006-10-25 2010-02-04 Marina Dobrovolskaia Nanoparticle-based anticoagulant
AU2008216669B2 (en) * 2007-02-15 2013-12-12 Mannkind Corporation A method for enhancing T cell response
CA2682580A1 (en) * 2007-03-30 2008-10-09 Duke University A method of modulating the activity of a nucleic acid molecule
AU2007359585A1 (en) 2007-09-27 2009-04-02 Sca Hygiene Products Ab Claylinked polymer gels
US20100285081A1 (en) 2007-11-12 2010-11-11 Massachusetts Institute Of Technology Bactericidal Nanofibers, and Methods of Use Thereof
WO2010020008A1 (en) 2008-08-22 2010-02-25 Polymers Crc Limited Polymer coatings
US8992991B2 (en) 2009-05-15 2015-03-31 The Johns Hopkins University Multicomponent degradable cationic polymers
IN2012DN02345A (enExample) 2009-09-16 2015-08-21 Univ Duke
WO2012088059A2 (en) 2010-12-20 2012-06-28 Virginia Commonwealth University A facile method for crosslinking and incorporating bioactive molecules into electrospun fiber scaffolds
US20140234373A1 (en) 2011-09-16 2014-08-21 Georfia Regents University Methods of Promoting Immune Tolerance

Also Published As

Publication number Publication date
CA2774460C (en) 2016-08-09
WO2011034583A3 (en) 2011-10-06
WO2011034583A2 (en) 2011-03-24
US20170095503A1 (en) 2017-04-06
US11617779B2 (en) 2023-04-04
EP2477641A2 (en) 2012-07-25
EP2477641A4 (en) 2013-08-07
US9468650B2 (en) 2016-10-18
EP2477641B1 (en) 2024-03-27
CA2774460A1 (en) 2011-03-24
CN102639142A (zh) 2012-08-15
US20120183564A1 (en) 2012-07-19
US20230248805A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
IN2012DN02345A (enExample)
EP2569453A4 (en) Nucleic Acid ISOLATION METHOD
WO2020198509A3 (en) Modified oligonucleotides with increased stability
BR112014005205A2 (pt) métodos para etiquetar bibliotecas codificadas com dna
WO2007136736A3 (en) Methods for nucleic acid sorting and synthesis
MX2010002113A (es) Metodos para detectar oligonucleotidos.
WO2007127219A3 (en) Targeted delivery to leukocytes using protein carriers
IL190501A0 (en) Multicomponent nucleic acid enzymes and methods for their use
IN2014DN03463A (enExample)
WO2008063203A3 (en) Compositions and methods for efficient gene silencing in plants
WO2008061537A3 (en) Oligonucleotides for modulating target rna activity
WO2008151631A3 (en) Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
WO2009012363A3 (en) Nucleotides and aptamers containing boronic acid groups having biased binding to glycosylated proteins, and uses thereof
EP3358014A3 (en) Method for stabilizing functional nucleic acids
WO2005097993A3 (en) Immunostimulatory viral rna oligonucleotides
EA201290612A1 (ru) Способ выделения нуклеиновой кислоты и набор для этого
WO2006019430A3 (en) Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
AR067135A1 (es) Metodos para aislar arn de fragmento largo de muestras fijas
WO2008092081A8 (en) Targeted delivery of sirna
AU2014219019A8 (en) Short interfering nucleic acid (siNA) molecules containing a 2' internucleoside linkage
EE200200051A (et) Tenastsiin C nukleiinhappelised ligandid
WO2011056073A3 (en) Novel compounds for modulating neovascularisation and methods of treatment using these compounds
BR112014021993A2 (pt) detecção da variação de nucleotídeo em sequência de ácido nucleico alvo através de ensaio de clivagem e extensão de pto
ATE548454T1 (de) Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis
MX362061B (es) Ácidos nucleicos de enlace c5a nuevos.